Insulet Corporation appointed Jonathan J. Mazelsky as a Class II director, effective July 1, 2026. Mr. Mazelsky, formerly the CEO of IDEXX Laboratories, Inc., will receive an initial grant of restricted stock units worth $216,548. Insulet Corporation is a medical technology company that develops and manufactures continuous glucose monitoring systems and insulin delivery systems.